(Q36360338)

13 August 2017

1 reference

title

Goserelin: a review of its use in the treatment of early breast cancer in premenopausal and perimenopausal women (English)

1 reference

13 August 2017

2

Greg L Plosker

1 reference

13 August 2017

4

Antona J Wagstaff

1 reference

13 August 2017

Susan M Cheer

1

1 reference

13 August 2017

Dene Simpson

series ordinal

3

1 reference

13 August 2017

publication date

1 January 2005

1 reference

13 August 2017

1 reference

13 August 2017

volume

65

1 reference

13 August 2017

issue

18

1 reference

13 August 2017

page(s)

2639-2655

1 reference

Anti-tumour activity of ICI 118630, a new potent luteinizing hormone-releasing hormone agonist

13 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200565180-00011

Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200565180-00011

Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study

21 January 2018

1 reference

12 December 2020

Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group

1 reference

12 December 2020

LH-RH agonist, Zoladex (Goserelin), depot formulation in the treatment of prostatic cancer. Randomized dose-finding trial in Japan

1 reference

12 December 2020

Adjuvant hormonal therapy for premenopausal women with breast cancer

1 reference

12 December 2020

Clinical pharmacokinetics of goserelin

1 reference

12 December 2020

Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 r

1 reference

12 December 2020

Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).

1 reference

12 December 2020

The effect of danazol and the LHRH agonist analogue goserelin (Zoladex) on the biological activity of luteinizing hormone in women with endometriosis

1 reference

12 December 2020

Endocrinologic and clinical evaluation following a single administration of a gonadotrophin-releasing hormone agonist (Zoladex), in a depot formulation, to premenopausal women

1 reference

12 December 2020

Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions

1 reference

12 December 2020

Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in benign gynaecological disorders

1 reference

12 December 2020

Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF)

1 reference

12 December 2020

Luteinizing hormone-releasing hormone analogues in early breast cancer: updated status of ongoing clinical trials

1 reference

12 December 2020

Treatment with a GnRH analogue: effects on hemostatic risk factors for thrombo-embolic disease

1 reference

12 December 2020

Cholesterol fractions and apolipoproteins during endometriosis treatment by a gonadotrophin releasing hormone (GnRH) agonist implant or by danazol

1 reference

12 December 2020

Overview of luteinizing hormone-releasing hormone agonists in early breast cancer-benefits of reversible ovarian ablation

1 reference

12 December 2020

Suppression of ovarian activity by Zoladex depot (ICI 118630), a long-acting luteinizing hormone releasing hormone agonist analogue

1 reference

12 December 2020

Factors associated with early menopause

1 reference

12 December 2020

The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women

1 reference

12 December 2020

Pharmacokinetic and endocrinological parameters of a slow-release depot preparation of the GnRH analogue ICI 118630 (zoladex) compared with a subcutaneous bolus and continuous subcutaneous infusion of the same drug in patients with prostatic cancer

1 reference

12 December 2020

Potent agonist and antagonist analogues of luliberin containing an azaglycine residue in position 10

1 reference

12 December 2020

Guidelines on endocrine therapy of breast cancer EUSOMA.

1 reference

12 December 2020

Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy

1 reference

12 December 2020

Survival analyses from the ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer

1 reference

12 December 2020

Therapeutic significance and the mechanism of action of the LH-RH agonist ICI 118630 in breast and prostate cancer

1 reference

12 December 2020

Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian

1 reference

12 December 2020

Experience with a depot GnRH-agonist (Zoladex) in the treatment of genital endometriosiss

1 reference

12 December 2020

Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer

1 reference

12 December 2020

Endocrine effects of goserelin, a new depot luteinising hormone releasing hormone agonist

1 reference

12 December 2020

Ovarian ablation in early breast cancer: overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

12 December 2020

Biodegradable sustained release formulation of the LH-RH analogue 'Zoladex' for the treatment of hormone-responsive tumours

1 reference

12 December 2020

Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.

1 reference

12 December 2020

A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer

1 reference

12 December 2020

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

12 December 2020

Management of premenopausal women with early-stage breast cancer: is there a role for ovarian suppression?

1 reference

12 December 2020

Goserelin (Zoladex)--its role in early breast cancer in pre- and perimenopausal women

1 reference

12 December 2020

Treatment With Different GnRH Analogues in Women: Preliminary Evidence for Disparant Effects on Serum Androgen Concentrations

1 reference

12 December 2020

A vision for the future?

1 reference

12 December 2020

Goserelin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in prostate cancer

1 reference

12 December 2020

National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000.

1 reference

12 December 2020

10.2165/00003495-200565180-00011

Identifiers

DOI

1 reference

Dimensions Publication ID

13 August 2017

1005414415

0 references

1 reference